Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04592913 · ClinicalTrials.gov registry record · Phase 3

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

A Phase 3 study of Gastrointestinal Neoplasms and Esophagogastric Junction, sponsored by AstraZeneca.

Active
Registry status
Phase 3
Development phase
957
Enrollment target
20
Study locations

NCT04592913 is a Phase 3 study of Gastrointestinal Neoplasms and Esophagogastric Junction that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 957 participants, roughly in line with the 887-participant average among 12 other Gastrointestinal Neoplasms trials with a reported enrollment target. The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04592913, a Phase 3 study of Gastrointestinal Neoplasms and Esophagogastric Junction, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
957 participants
Enrollment target
20
Study locations

Study Summary

This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC) (MATTERHORN).

Conditions Studied

Gastrointestinal Neoplasms Esophagogastric Junction

Interventions

  • DRUG Durvalumab
  • DRUG FLOT chemotherapy

Study Locations (20)

California

  • Research Site - Duarte
  • Research Site - Los Angeles
  • Research Site - Los Angeles
  • Research Site - Sylmar

Other

  • Research Site - Buenos Aires
  • Research Site - Ciudad Autonoma Buenos Aires
  • Research Site - Ciudad de Buenos Aires
  • Research Site - Ciudad de Buenos Aires

Florida

  • Research Site - St. Petersburg
  • Research Site - Tallahassee
  • Research Site - West Palm Beach

New York

  • Research Site - New York
  • Research Site - Rochester

Texas

  • Research Site - Dallas
  • Research Site - Lancaster

Indiana

  • Research Site - Fort Wayne

Kentucky

  • Research Site - Louisville

Massachusetts

  • Research Site - Boston

Trial Details

FieldValue
Enrollment Target 957 participants
Start Date 2020-11-17
Est. Completion 2027-09-27
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04592913

The ClinicalTrials.gov registry entry for NCT04592913 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 957 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 887-participant average among 12 other Gastrointestinal Neoplasms trials with a reported enrollment target. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Gastrointestinal Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Durvalumab is the first listed.

NCT04592913 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Other, Florida.

Frequently Asked Questions

What is clinical trial NCT04592913 about?

NCT04592913 is a clinical study titled "Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer". This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC) (MATTERHORN).

What is the current status of trial NCT04592913?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 957 participants. The study started on 2020-11-17. Estimated completion is 2027-09-27.

What conditions does trial NCT04592913 study?

This clinical trial studies the following conditions: Gastrointestinal Neoplasms, Esophagogastric Junction.

What interventions are being tested in trial NCT04592913?

The interventions under investigation include: Durvalumab (DRUG), FLOT chemotherapy (DRUG).

Who is sponsoring clinical trial NCT04592913?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04592913 being conducted?

This trial has 20 study locations across California, Florida, Indiana, Kentucky, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastrointestinal Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastrointestinal Neoplasms

All registered trials for this condition

Esophagogastric Junction

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.